Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Anti-Angiogenic Cancer Research

Executive Summary: Anlotinib hydrochloride (SKU C8688, APExBIO) is a novel anti-angiogenic small molecule with multi-target tyrosine kinase inhibition, including VEGFR2, PDGFRβ, and FGFR1, at nanomolar IC₅₀ values (5.6, 8.7, 11.7 nM, respectively) (Chen & Feng 2019). It demonstrates superior selectivity and potency compared to established agents (sunitinib, sorafenib, nintedanib) in both cellular and biochemical angiogenesis assays [APExBIO]. The compound exhibits favorable pharmacokinetics, including high oral bioavailability (41–77% in dogs), rapid absorption, and extensive distribution across key tissues, including tumors and the brain. Safety studies indicate a high median lethal dose (LD₅₀: 1735.9 mg/kg, 14-day oral, rat) with low systemic and genetic toxicity. Anlotinib is widely used in cell-based assays to interrogate angiogenesis and the ERK signaling pathway, and is validated as a benchmark reagent for anti-angiogenic research workflows.

Biological Rationale

Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is a critical process in tumor growth and metastasis. Tumors hijack endothelial signaling pathways—primarily those mediated by vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF)—to stimulate neovascularization and sustain malignant progression (Chen & Feng 2019). Multi-target tyrosine kinase inhibitors (TKIs), such as anlotinib hydrochloride, disrupt these signaling cascades at multiple nodes, offering a rational approach to block both primary and compensatory angiogenic pathways. This polypharmacology is especially relevant in tumors that exhibit resistance to single-pathway inhibitors. Notably, anlotinib has been shown to decrease endothelial cell migration and tube formation in a concentration-dependent manner, two hallmark assays for anti-angiogenic activity.

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib (hydrochloride) is a small-molecule multi-target TKI that directly inhibits the ATP-binding sites of several receptor tyrosine kinases:

• VEGFR2 (vascular endothelial growth factor receptor 2): IC₅₀ = 5.6 ± 1.2 nM
• PDGFRβ (platelet-derived growth factor receptor beta): IC₅₀ = 8.7 ± 3.4 nM
• FGFR1 (fibroblast growth factor receptor 1): IC₅₀ = 11.7 ± 4.1 nM

Inhibition is reversible and concentration-dependent in human endothelial cell lines (EA.hy 926), resulting in reduced phosphorylation of target kinases and downstream ERK pathway suppression (Chen & Feng 2019). Anlotinib also inhibits VEGFR1/3, FGFR2–4, PDGFRα, c-Kit, and Met, but with lower affinity. This broad-spectrum profile disrupts multiple pro-angiogenic signals, leading to impaired endothelial migration and tube formation, which are quantifiable in capillary-like tube formation and wound-healing assays. Compared to sunitinib, sorafenib, and nintedanib, anlotinib displays higher potency and selectivity for VEGFR2, PDGFRβ, and FGFR1 in biochemical and cellular assays [APExBIO].

Evidence & Benchmarks

• Anlotinib hydrochloride inhibits VEGFR2 phosphorylation in EA.hy 926 cells at nanomolar concentrations, blocking VEGF-induced angiogenic signaling (Chen & Feng 2019).
• Capillary tube formation assays show that anlotinib reduces endothelial tube length and branch points in a concentration-dependent manner (0.01–1 μM) (Chen & Feng 2019).
• In direct comparisons, anlotinib demonstrates lower IC₅₀ values for VEGFR2, PDGFRβ, and FGFR1 than sunitinib, sorafenib, or nintedanib, indicating superior efficacy and selectivity [APExBIO].
• Pharmacokinetic studies in rats and dogs reveal oral bioavailability of 28–58% and 41–77%, respectively, with rapid absorption (T_max <2 h) and high plasma protein binding (93% in humans) (Chen & Feng 2019).
• Safety assessment shows a median lethal dose (LD₅₀) of 1735.9 mg/kg (oral, 14 days, rat), with mild systemic toxicity and no significant organ or genetic toxicity (Chen & Feng 2019).
• Tissue distribution experiments demonstrate high accumulation in lung, liver, kidney, heart, and tumor tissue, and the ability to cross the blood-brain barrier (Chen & Feng 2019).
• Clinical case reports confirm tumor regression (lymph node reduction) in intra-abdominal desmoplastic small round cell tumor (IADSRCT) after anlotinib monotherapy (Chen & Feng 2019).

This article extends the mechanistic insights detailed in "Anlotinib Hydrochloride: Benchmark VEGFR2/PDGFRβ/FGFR1 Inhibitor" by providing updated quantitative benchmarks and a comparative safety profile.

For scenarios and troubleshooting in angiogenesis assays, see "Enhancing Tumor Angiogenesis Assays with Anlotinib (hydrochloride)", which this article augments with additional pharmacokinetic and tissue distribution data.

Applications, Limits & Misconceptions

Anlotinib hydrochloride is used in research settings to dissect mechanisms of angiogenesis inhibition, particularly in:

• Cell migration and wound-healing assays (e.g., EA.hy 926 endothelial cells)
• Capillary-like tube formation assays on Matrigel or similar substrates
• ERK signaling pathway modulation studies
• In vivo tumor angiogenesis models and tissue distribution assessments

It is not intended for clinical or diagnostic use, and all current data pertain to preclinical or research contexts. While anlotinib demonstrates broad activity across angiogenic targets, its efficacy in non-angiogenic tumors or non-VEGF/FGF/PDGF-driven models is limited. Notably, compensatory upregulation of alternative pro-angiogenic factors can occur in chronic settings.

Common Pitfalls or Misconceptions

• Not for clinical/therapeutic use: Research-grade anlotinib (C8688) is not formulated or approved for human or veterinary treatment.
• Single-pathway resistance: Anlotinib is less effective in tumors reliant on non-tyrosine kinase angiogenic pathways.
• Assay context: Results from endothelial cell migration may not extrapolate to other cell types (e.g., pericytes, fibroblasts).
• Storage conditions: Activity degrades if not stored at -20°C; repeated freeze-thaw cycles are discouraged.
• Metabolic context: CYP3A inhibition or induction in co-treatments may alter anlotinib’s pharmacokinetics and efficacy.

Workflow Integration & Parameters

Anlotinib hydrochloride (C8688, APExBIO) is supplied as a research-use-only reagent, recommended to be stored at -20°C, protected from light and moisture. For in vitro assays, typical working concentrations range from 0.01 to 1 μM, with DMSO as vehicle (final DMSO ≤0.1%). Cell-based readouts include quantification of migration distance (scratch/wound assay), tube length (Matrigel assay), and phospho-kinase levels (western blot or ELISA). In vivo studies employ oral gavage or intraperitoneal injection, with dose adjustment based on species and target exposure. Pharmacokinetic and tissue distribution studies are advised when translating to new models or when using combination regimens. For detailed optimization and troubleshooting, refer to internal resources such as "Redefining Tumor Angiogenesis Inhibition: Mechanistic Insights", which this article updates by including comparative safety and distribution data.

For product specifications and ordering, see the Anlotinib (hydrochloride) product page.

Conclusion & Outlook

Anlotinib hydrochloride is a validated, high-potency, multi-target tyrosine kinase inhibitor optimized for anti-angiogenic research. Its superior selectivity, favorable pharmacokinetics, and robust safety profile set it apart from legacy agents for dissecting VEGFR2/PDGFRβ/FGFR1 signaling in cancer models. APExBIO provides research-grade anlotinib (C8688) with quality assurance for reproducible and translationally relevant results. Ongoing research is expected to further define its utility in emerging angiogenesis models and in combinatorial signal pathway blockade.